[18F]fluorodeoxyglucose positron emission tomography for outcome prediction of mammalian target of rapamycin inhibitor therapy

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages

  De Giorgi, Ugo ^a   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; GEMCITABINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; DIAGNOSTIC AGENT; FLUORINE; FLUORODEOXYGLUCOSE F 18; PROTEIN SERINE THREONINE KINASE; RADIOPHARMACEUTICAL AGENT; SIGNAL PEPTIDE;

DISEASE COURSE; LETTER; NONHUMAN; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; DISEASE FREE SURVIVAL; HUMAN; METABOLISM; NEOPLASM; NOTE; SCINTISCANNING;

ANTIBIOTICS, ANTINEOPLASTIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN-SERINE-THREONINE KINASES; RADIOPHARMACEUTICALS; SIROLIMUS; TREATMENT OUTCOME;

EID: 77956404449     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.6866     Document Type: Letter

References (14)

1. 18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol 27:2697-2704, 2009
2. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations-European Organisation for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782, 1999
3. Jimeno A, Rudek MA, Kulesza P, et al: Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors. J Clin Oncol 26:4172-4179, 2008
4. De Giorgi U, Valero V, Rohren E, et al: Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. J Clin Oncol 27:3303-3311, 2009
5. Weber WA: Assessing tumor response to therapy. J Nucl Med 50:1S-10S, 2009 (suppl 1)
6. Komar G, Kauhanen S, Liukko K, et al: Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 15:5511-5517, 2009
7. Podoloff DA, Ball DW, Ben-Josef E, et al: NCCN task force: Clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 7:S1-S26, 2009 (suppl 2)
8. Benz MR, Czernin J, Allen-Auerbach MS, et al: FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res 15:2856-2863, 2009
9. de Geus-Oei LF, Vriens D, van Laarhoven HW, et al: Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: A systematic review. J Nucl Med 50:S43-S54, 2009 (suppl 1)
10. Garin E, Le Jeune F, Devillers A, et al: Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 50:858-864, 2009
11. Konings IR, Verweij J, Wiemer EA, et al: The applicability of mTOR inhibition in solid tumors. Curr Cancer Drug Targets 9:439-450, 2009
12. Sawyers C: Will kinase inhibitors have a dark side? N Engl J Med 355:313-315, 2006
13. Neshat MS, Mellinghoff IK, Tran C, et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98:10314-10319, 2001 (Pubitemid 32803017)
14. O'Reilly KE, Rojo F, She QB, et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66:1500-1508, 2006 (Pubitemid 43259931)